IP Library Granted Patent US 9,926,367
Granted Patent B2
US 9,926,367 · App. 15/430,100 · Granted Mar 27, 2018

Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof

Inventors: Rocco Jamie Rotello (Lebanon, OH); Kevin Gene Peters (Cincinnati, OH); Michael Glenn Davis (Lebanon, OH)
Assignee: AERPIO THERAPEUTICS, INC.
C07K16/18C07K16/28C07K16/40A61K2039/505C07K2317/55C07K2317/73C07K2317/75C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,926,367
App. No.
15/430,100
Granted
Mar 27, 2018
Kind
B2
Abstract

Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.

Claims (11)

1. A method for regulating Tie-2 receptor activation in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of a humanized form of R15E6 that activates the Tie-2 receptor, wherein administration of the humanized form of R15E6 to the subject activates the Tie-2 receptor in the presence of Ang1.

2. The method of claim 1 , wherein the humanized form of R15E6 does not bind the Tie-2 receptor.

3. The method of claim 1 , wherein administration of the humanized form of R15E6 to the subject enhances VEGF-mediated endothelial cell survival in a dose dependent manner.

4. The method of claim 3 , wherein administration of the humanized form of R15E6 to the subject enhances FGF-mediated endothelial cell survival in a dose dependent manner.

5. The method of claim 1 , wherein administration of the humanized form of R15E6 to the subject activates the Tie-2 receptor in the presence of Ang1 to a greater degree than in the absence of Ang1.

6. A method of enhancing Tie-2 receptor phosphorylation in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a humanized form of R15E6, wherein the humanized form of R15E6 enhances Ang1-induced Tie-2 activation.

7. The method of claim 6 , wherein the humanized form of R15E6 does not bind the Tie-2 receptor.

8. The method of claim 6 , wherein the humanized form of R15E6 enhances Ang1-induced Tie-2 receptor phosphorylation in the presence of VEGF.

9. The method of claim 8 , wherein the humanized form of R15E6 enhances Ang1-induced Tie-2 receptor phosphorylation in the presence of FGF.

10. The method of claim 1 , wherein the humanized form of R15E6 binds to SEQ ID NO: 3.

11. The method of claim 6 , wherein the humanized form of R15E6 binds to SEQ ID NO: 3.

Assignments (5)
CHANGE OF NAME Recorded Jan 26, 2026
From: EYEPOINT PHARMACEUTICALS, INC.
To: EYEPOINT, INC.
Reel/Frame 074489/0618 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 057448/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2020
From: AERPIO THERAPEUTICS LLC
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 052432/0789 →
CHANGE OF NAME Recorded Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049920/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: ROTELLO, ROCCO JAMIE; PETERS, KEVIN GENE; DAVIS, MICHAEL GLENN
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 041804/0742 →
Continuity (6)
Continuation 13958990 · Aug 5, 2013
Division 13115180 · May 25, 2011
Division 11784094 · Apr 5, 2007
Provisional Application 60798896 · May 9, 2006
Provisional Application 60790506 · Apr 7, 2006
Related Publication 20170349649A1 · Dec 7, 2017